Piper Sandler Lowers ResMed (NYSE:RMD) Price Target to $225.00

Key Points

• Piper Sandler lowered ResMed’s price target to $225 from $233 while maintaining a “neutral” rating, implying roughly 7.5% upside from the stock’s $209.29 closing price.
• Analyst sentiment remains cautious: ResMed has a consensus “Hold” rating and an average price target of $239.33, with several firms recently reducing targets or downgrading ratings.
• ResMed exceeded quarterly EPS expectations, reporting $2.95 versus $2.89 estimated, while revenue rose 8.6% year over year to $1.46 billion. Executives and directors also sold shares under pre-arranged Rule 10b5-1 plans.

ResMed (NYSE:RMD - Get Free Report) had its price target reduced by stock analysts at Piper Sandler from $233.00 to $225.00 in a research report issued on Friday,Benzinga reports. The firm currently has a "neutral" rating on the medical equipment provider's stock. Piper Sandler's price target points to a potential upside of 7.51% from the company's current price.

A number of other brokerages have also weighed in on RMD. Royal Bank Of Canada lowered shares of ResMed from an "outperform" rating to a "sector perform" rating and set a $234.00 price target on the stock. in a research note on Thursday, July 16th. Mizuho cut their price objective on ResMed from $235.00 to $220.00 and set an "outperform" rating for the company in a research note on Wednesday, July 15th. Weiss Ratings cut ResMed from a "hold (c)" rating to a "hold (c-)" rating in a report on Friday, July 24th. Evercore set a $255.00 target price on ResMed and gave the company an "outperform" rating in a research report on Monday, April 13th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and issued a $230.00 price target (down from $286.00) on shares of ResMed in a research note on Wednesday, June 17th. Seven analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $239.33.

ResMed Price Performance

ResMed stock traded down $13.95 during trading on Friday, reaching $209.29. The company had a trading volume of 1,992,643 shares, compared to its average volume of 1,295,438. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 3.01. The firm's 50-day simple moving average is $200.06 and its 200 day simple moving average is $222.30. The firm has a market capitalization of $30.36 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 1.36 and a beta of 0.76. ResMed has a 1-year low of $180.26 and a 1-year high of $293.81.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.89 by $0.06. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.46 billion. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The company's revenue was up 8.6% compared to the same quarter last year. During the same period last year, the firm posted $2.55 earnings per share. As a group, equities research analysts anticipate that ResMed will post 11.14 earnings per share for the current fiscal year.

Insider Buying and Selling at ResMed

In other news, Director Peter C. Farrell sold 8,000 shares of the business's stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total transaction of $1,800,000.00. Following the transaction, the director owned 52,773 shares of the company's stock, valued at approximately $11,873,925. The trade was a 13.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael J. Farrell sold 4,991 shares of the company's stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the sale, the chief executive officer directly owned 466,223 shares of the company's stock, valued at $101,893,036.65. This represents a 1.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 17,982 shares of company stock valued at $3,858,837. 0.65% of the stock is owned by company insiders.

Institutional Trading of ResMed

Hedge funds have recently made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in ResMed in the fourth quarter valued at approximately $25,000. Bell Investment Advisors Inc acquired a new stake in ResMed during the second quarter worth $26,000. Imprint Wealth LLC acquired a new stake in ResMed during the third quarter worth $26,000. WFA of San Diego LLC purchased a new stake in ResMed in the second quarter valued at $26,000. Finally, Sunbelt Securities Inc. purchased a new stake in ResMed in the third quarter valued at $31,000. Hedge funds and other institutional investors own 54.98% of the company's stock.

Key ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal fourth-quarter EPS of $2.95, above the approximately $2.89–$2.90 consensus and up from $2.55 a year earlier. Revenue rose 8.6% year over year to $1.46 billion, matching expectations and supporting the company’s ongoing growth story. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company increased its dividend while reporting strong fourth-quarter and full-year fiscal 2026 results, which could enhance ResMed’s appeal to income-focused investors. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Neutral Sentiment: Despite the EPS beat, revenue was merely in line with forecasts. Analysts maintain an overall “Hold” view, reflecting mixed expectations for future growth amid tariff, inflation and healthcare-spending pressures. ResMed Receives Average Hold Rating
• Negative Sentiment: Wells Fargo lowered its price target from $225 to $215 and reiterated an “equal weight” rating, leaving limited implied upside based on the latest quoted price. The reduction reinforces concerns that the earnings results may already be reflected in the valuation. Benzinga Analyst Target Update
• Negative Sentiment: Director Peter Farrell sold 8,000 shares for approximately $1.8 million. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, its negative signaling value is limited, but it may still contribute modest selling pressure. SEC Insider Trading Filing

ResMed Company Profile

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source